

REMARKS

The April 9, 2003 Office Communication forwarding a Notice to Comply stated that the application fails to comply with the requirements of 37 CFR 1.821 and 1.825 and requests submission of a corrected sequence listing in both paper and computer readable form. It is respectfully submitted that the amendment herewith places the application in compliance such that a new copy of the sequence listing is not required.

Specifically, the Office Communication states that Figure 6 depicts amino acid sequences for which SEQ ID NOs were not presented in either the figure itself or in the brief description of the figure.

The amendment submitted herewith adds SEQ ID NOs to the brief description of Figure 6, such that all of the amino acid sequences present in Figure 6 are now identified by SEQ ID NOs. Further, it is respectfully submitted that Figure 6 and the brief description of Figure 6 contain references to SEQ ID NOs: 59-70, all of which were present in the sequence listing filed on July 19, 2002.

Thus, it is respectfully submitted that the July 19, 2002 sequence listing is accurate and in full compliance with the rules regarding applications containing sequence listings. The amendments herewith merely serve to accurately identify the sequences depicted in Figure 6 with the appropriate SEQ ID NOs. Thus, this amendment does not add additional sequences to the sequence listing filed July 19, 2002, such that a new copy of the sequence listing is not required.

Consequently, reconsideration and withdrawal of the Office Communication forwarding a Notice to Comply is respectfully requested.


CONCLUSION

Reconsideration and withdrawal reconsideration and withdrawal of the Office Communication and Notice to Comply is respectfully requested in view of the remarks herein. The Examiner is invited to telephone the undersigned if any questions remain regarding the validity of the previously submitted sequence listing.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP
Attorneys for the Applicant

By:



Thomas J. Kowalski
Reg. No. 32,147
(212) 588-0800

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

Please replace the paragraph beginning on page 11, line 12 with the following rewritten paragraph:

Figure 6 shows a schematic diagram of CTLA-4 VLD loop replacements. The constructs are labeled A-I. Construct A (CTLA-4 VLD: S2) represents the wild-type CTLA-4 extracellular V-domain, spanning residues 1-115 (SEQ ID NOs: 59, 61 and 62). Constructs B (CTLA-4-Som1; PP2) and C (CTLA-4-Som1-Cys120; PP5) both contain the 14 residue somatostatin polypeptide in CDR1 (SEQ ID NOs: 60, 61 and 62). PP5 also carries a C-terminal extension containing Cys120. Construct D (CTLA-4-Som3; PP8) contains the 14 residue somatostatin polypeptide in place of CDR3 (SEQ ID NOs: 59, 61 and 60). In construct E (CTLA-4-HA2:XX4), CDR2 has been replaced with a haemagglutinin tag (SEQ ID NOs: 59, 63 and 62). In construct F (CTLA-4-Som1-Som3: VV3), both CDR1 and CDR3 have been replaced with the somatostatin polypeptide (SEQ ID NOs: 60, 61 and 60). In construct G (CTLA-4-Som-HA2-Som3: ZZ3) CDR1 and CDR3 are replaced with the somatostatin polypeptide whilst CDR2 is replaced with haemagglutinin tag (SEQ ID NOs: 60, 63 and 60). In construct H (CTLA-4-anti-lys:2V8), all three CDR loop structures have been replaced with the CDR loops from a camel anti-lysozyme V_HH molecule (SEQ ID NOs: 64, 65 and 66). Construct I (CTLA-4-anti-mel: 3E4) represents CTLA-4 VLD in which all three CDRs have been replaced by the VH CDR loops from anti-melanoma antibody V86 (Cai And Garen, 1997) (SEQ ID NOs: 67, 68 and 69). PelB, cleavable pectate lyase secretion sequence (22 aa); flag, dual flag tag (AAADYKDDDDKAADYKDDDDK) (SEQ ID NO: 70).